Diverticulitis Disease Market Report 2026

Diverticulitis Disease Market Overview

• Diverticulitis Disease market size has reached to $2.02 billion in 2025 • Expected to grow to $3.22 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Smoking's Role In Fueling Diverticulitis Market Growth • Market Trend: Innovative Drug Development Spurs Advances In Diverticulitis Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Diverticulitis Disease Market?

Diverticulitis disease refers to a medical condition characterized by inflammation or infection of small pouches that develop in the walls of the colon or large intestine. The symptoms of diverticular disease include lower abdominal pain, constipation, diarrhea and rectal bleeding. The main types of diverticulitis disease are uncomplicated and complicated. Uncomplicated diverticulitis refers to a medical condition characterized by inflammation or infection of small pouches (diverticula) that can form in the walls of the colon. The types of diagnosis are included, such as computed tomography (CT) scans, ultrasounds, urine tests and blood tests, that includes treatments types such as medications, surgery, supportive care, penicillin antibiotic, antibiotics, dietary supplements and intravenous (IV) fluids. It is used by several end-users, such as specialty centers, hospitals and research centers.

What Is The Diverticulitis Disease Market Growth Forecast?

The diverticulitis disease market size is expected to see strong growth in the next few years. It will grow to $3.22 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to preventive digestive health awareness, improved imaging access, outpatient care expansion, reduced surgical intervention rates, focus on lifestyle modification. Major trends in the forecast period include increasing diagnosis of uncomplicated diverticulitis cases, rising preference for conservative and outpatient management, growing use of imaging-based diagnostic techniques, expansion of antibiotic and supportive care treatment, higher awareness of dietary and lifestyle management.

Global Diverticulitis Disease Market Segmentation

1) By Type: Uncomplicated, Complicated 2) By Diagnosis: Computed Tomography (Ct) Scan, Ultrasound, Urine Test, Blood Test 3) By Treatment: Medications, Surgery, Supportive Care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (Iv) Fluids 4) By End-User: Specialty Centers, Hospitals, Research Centers Subsegments: 1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy 2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

What Are The Drivers Of The Diverticulitis Disease Market?

The rising prevalence of smoking addiction is expected to propel the growth of the diverticulitis disease market going forward. Smoking addiction refers to the compulsive dependence on nicotine-containing products such as cigarettes, vapes, and other tobacco items. The prevalence of smoking addiction is increasing due to aggressive marketing, greater social acceptability, stress-related triggers, and the expanding availability of e-cigarettes and vaping devices. Diverticulitis treatment supports this trend because smoking reduces blood flow to the colon and increases the risk and severity of diverticular disease, thereby elevating the need for diagnosis and therapeutic management. For instance, in October 2024, according to the European Respiratory Society's (ERS), a Switzerland-based non-profit organization, a study covering smoking trends among young people revealed a significant rise in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024.Therefore, the rising prevalence of smoking addiction will drive the growth of the diverticulitis disease industry. The increasing prevalence of diabetes is expected to propel the growth of the diverticulitis disease market going forward. Diabetes refers to a chronic metabolic disorder characterized by elevated blood glucose levels resulting from impaired insulin production or utilization. The increasing prevalence of diabetes is primarily driven by unhealthy diets high in processed foods, sedentary lifestyles, rising obesity rates, and aging populations. Diverticulitis disease market supports this trend by addressing diabetes-related complications, as high blood glucose weakens blood vessels and increases colon susceptibility to infections and inflammation, thereby increasing the demand for diagnostic and therapeutic interventions. For instance, in June 2024, according to the National Health Service (NHS England), a UK-based publicly funded healthcare system, in 2023 the number of individuals identified with pre-diabetes increased to 3,615,330, representing an 18% rise from 3,065,825 in 2022, and among people under 40, cases rose nearly 25% from 173,166 in 2022 to 216,440 in 2023. Therefore, the increasing prevalence of diabetes is driving the growth of the diverticulitis disease industry.

Key Players In The Global Diverticulitis Disease Market

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Global Diverticulitis Disease Market Trends and Insights

Major companies operating in the diverticulitis disease market are developing innovative drugs and getting them approved to sustain their position in the market. Drug development can lead to the development of more effective treatments for diverticulitis, reducing the risk of complications and improving patient outcomes. For instance, in April 2023, the United States Food and Drug Administration, a US-based federal organization, approved Seres' microbiota drug for recurrent gut infections. This drug is designed to treat recurring gut infections and prevent the recurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and over. The approval of Vowst was based on a clinical trial that enrolled 346 patients with recurrent CDI. The trial found that patients who received Vowst were significantly less likely to experience a recurrence of the infection than those who received a placebo. The drug is taken orally and is based on microbiota containing Firmicutes spores, which are known to contribute to a healthy microbiome that can resist C. diff. colonization..

Regional Outlook

North America was the largest region in the diverticulitis disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diverticulitis Disease Market?

The diverticulitis disease market consists of revenues earned by entities by providing diagnostic services, pain management, nutritional therapy and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diverticulitis disease market also includes sales of antibiotics, dietary supplements, high-fiber foods and pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diverticulitis Disease Market Report 2026?

The diverticulitis disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diverticulitis disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.